AstraZeneca's CEO Pascal Soriot has bought 20,000 shares of the firm for over GBP2 million (USD2.5 million) to consolidate investor confidence after GBP50 billion (USD63 billion) was wiped out from the stock market in the past month, which may have been caused by China's anti-graft investigation on its country president and disappointing trial results of its lung cancer drug Dato-DXd.